Which has stronger earnings & valuation, HTFL or FLGT?

Fulgent Genetics has higher revenue and earnings than Heartflow. Fulgent Genetics is trading at a lower price-to-earnings ratio than Heartflow, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Heartflow $176.03M 12.82 -$116.79M -$3.11 N/A Fulgent Genetics $320.35M 1.81 -$60.51M -$2.39 N/A

Does the media prefer HTFL or FLGT?

In the previous week, Heartflow and Heartflow both had 6 articles in the media. Heartflow's average media sentiment score of 1.24 beat Fulgent Genetics' score of 0.90 indicating that Heartflow is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Heartflow 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fulgent Genetics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SGRY or FLGT?

In the previous week, Fulgent Genetics had 3 more articles in the media than Surgery Partners. MarketBeat recorded 6 mentions for Fulgent Genetics and 3 mentions for Surgery Partners. Surgery Partners' average media sentiment score of 0.93 beat Fulgent Genetics' score of 0.90 indicating that Surgery Partners is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Surgery Partners 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fulgent Genetics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor VRDN or FLGT?

In the previous week, Fulgent Genetics had 3 more articles in the media than Viridian Therapeutics. MarketBeat recorded 6 mentions for Fulgent Genetics and 3 mentions for Viridian Therapeutics. Viridian Therapeutics' average media sentiment score of 1.22 beat Fulgent Genetics' score of 0.90 indicating that Viridian Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viridian Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fulgent Genetics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer FLGT or AVAH?

In the previous week, Fulgent Genetics had 2 more articles in the media than Aveanna Healthcare. MarketBeat recorded 6 mentions for Fulgent Genetics and 4 mentions for Aveanna Healthcare. Fulgent Genetics' average media sentiment score of 0.90 beat Aveanna Healthcare's score of 0.76 indicating that Fulgent Genetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fulgent Genetics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aveanna Healthcare 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ADUS or FLGT?

In the previous week, Fulgent Genetics had 4 more articles in the media than Addus HomeCare. MarketBeat recorded 6 mentions for Fulgent Genetics and 2 mentions for Addus HomeCare. Addus HomeCare's average media sentiment score of 1.07 beat Fulgent Genetics' score of 0.90 indicating that Addus HomeCare is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Addus HomeCare 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fulgent Genetics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Fulgent Genetics (FLGT) Competitors

$20.42 -0.13 (-0.63%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$20.43 +0.01 (+0.04%)

As of 07:07 AM Eastern

Compare

FLGT vs. HTFL, SGRY, VRDN, AVAH, and ADUS

Should you buy Fulgent Genetics stock or one of its competitors? MarketBeat compares Fulgent Genetics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Fulgent Genetics include Heartflow (HTFL), Surgery Partners (SGRY), Viridian Therapeutics (VRDN), Aveanna Healthcare (AVAH), and Addus HomeCare (ADUS). These companies are all part of the "healthcare" industry.

How does Fulgent Genetics compare to Heartflow?

Heartflow (NASDAQ:HTFL) and Fulgent Genetics (NASDAQ:FLGT) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, media sentiment, risk, institutional ownership and earnings.

48.1% of Fulgent Genetics shares are held by institutional investors. 7.7% of Heartflow shares are held by insiders. Comparatively, 36.2% of Fulgent Genetics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Fulgent Genetics has higher revenue and earnings than Heartflow. Fulgent Genetics is trading at a lower price-to-earnings ratio than Heartflow, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heartflow	$176.03M	12.82	-$116.79M	-$3.11	N/A
Fulgent Genetics	$320.35M	1.81	-$60.51M	-$2.39	N/A

In the previous week, Heartflow and Heartflow both had 6 articles in the media. Heartflow's average media sentiment score of 1.24 beat Fulgent Genetics' score of 0.90 indicating that Heartflow is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Heartflow	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fulgent Genetics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Heartflow currently has a consensus price target of $37.00, suggesting a potential upside of 41.44%. Fulgent Genetics has a consensus price target of $27.00, suggesting a potential upside of 32.22%. Given Heartflow's stronger consensus rating and higher possible upside, equities analysts plainly believe Heartflow is more favorable than Fulgent Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heartflow	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.70
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Fulgent Genetics has a net margin of -23.04% compared to Heartflow's net margin of -58.42%. Heartflow's return on equity of 0.00% beat Fulgent Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heartflow	-58.42%	N/A	-20.02%
Fulgent Genetics	-23.04%	-3.24%	-2.97%

Summary

Heartflow beats Fulgent Genetics on 8 of the 15 factors compared between the two stocks.

How does Fulgent Genetics compare to Surgery Partners?

Surgery Partners (NASDAQ:SGRY) and Fulgent Genetics (NASDAQ:FLGT) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

48.1% of Fulgent Genetics shares are held by institutional investors. 2.0% of Surgery Partners shares are held by insiders. Comparatively, 36.2% of Fulgent Genetics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Surgery Partners currently has a consensus price target of $22.18, suggesting a potential upside of 38.81%. Fulgent Genetics has a consensus price target of $27.00, suggesting a potential upside of 32.22%. Given Surgery Partners' stronger consensus rating and higher probable upside, research analysts plainly believe Surgery Partners is more favorable than Fulgent Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surgery Partners	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Surgery Partners has a beta of 1.89, suggesting that its share price is 89% more volatile than the broader market. Comparatively, Fulgent Genetics has a beta of 0.89, suggesting that its share price is 11% less volatile than the broader market.

In the previous week, Fulgent Genetics had 3 more articles in the media than Surgery Partners. MarketBeat recorded 6 mentions for Fulgent Genetics and 3 mentions for Surgery Partners. Surgery Partners' average media sentiment score of 0.93 beat Fulgent Genetics' score of 0.90 indicating that Surgery Partners is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Surgery Partners	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fulgent Genetics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Fulgent Genetics has lower revenue, but higher earnings than Surgery Partners. Surgery Partners is trading at a lower price-to-earnings ratio than Fulgent Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surgery Partners	$3.31B	0.63	-$77.90M	-$0.60	N/A
Fulgent Genetics	$320.35M	1.81	-$60.51M	-$2.39	N/A

Surgery Partners has a net margin of -2.28% compared to Fulgent Genetics' net margin of -23.04%. Surgery Partners' return on equity of 1.04% beat Fulgent Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Surgery Partners	-2.28%	1.04%	0.41%
Fulgent Genetics	-23.04%	-3.24%	-2.97%

Summary

Surgery Partners beats Fulgent Genetics on 11 of the 17 factors compared between the two stocks.

How does Fulgent Genetics compare to Viridian Therapeutics?

Viridian Therapeutics (NASDAQ:VRDN) and Fulgent Genetics (NASDAQ:FLGT) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends, profitability and media sentiment.

48.1% of Fulgent Genetics shares are held by institutional investors. 2.4% of Viridian Therapeutics shares are held by company insiders. Comparatively, 36.2% of Fulgent Genetics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Viridian Therapeutics currently has a consensus target price of $38.79, indicating a potential upside of 104.24%. Fulgent Genetics has a consensus target price of $27.00, indicating a potential upside of 32.22%. Given Viridian Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Viridian Therapeutics is more favorable than Fulgent Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viridian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Fulgent Genetics has higher revenue and earnings than Viridian Therapeutics. Fulgent Genetics is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viridian Therapeutics	$70.85M	27.63	-$342.60M	-$3.32	N/A
Fulgent Genetics	$320.35M	1.81	-$60.51M	-$2.39	N/A

Fulgent Genetics has a net margin of -23.04% compared to Viridian Therapeutics' net margin of -490.31%. Fulgent Genetics' return on equity of -3.24% beat Viridian Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viridian Therapeutics	-490.31%	-80.19%	-48.84%
Fulgent Genetics	-23.04%	-3.24%	-2.97%

Viridian Therapeutics has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market. Comparatively, Fulgent Genetics has a beta of 0.89, meaning that its share price is 11% less volatile than the broader market.

In the previous week, Fulgent Genetics had 3 more articles in the media than Viridian Therapeutics. MarketBeat recorded 6 mentions for Fulgent Genetics and 3 mentions for Viridian Therapeutics. Viridian Therapeutics' average media sentiment score of 1.22 beat Fulgent Genetics' score of 0.90 indicating that Viridian Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viridian Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fulgent Genetics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Fulgent Genetics beats Viridian Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Fulgent Genetics compare to Aveanna Healthcare?

Fulgent Genetics (NASDAQ:FLGT) and Aveanna Healthcare (NASDAQ:AVAH) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.

In the previous week, Fulgent Genetics had 2 more articles in the media than Aveanna Healthcare. MarketBeat recorded 6 mentions for Fulgent Genetics and 4 mentions for Aveanna Healthcare. Fulgent Genetics' average media sentiment score of 0.90 beat Aveanna Healthcare's score of 0.76 indicating that Fulgent Genetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fulgent Genetics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aveanna Healthcare	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aveanna Healthcare has higher revenue and earnings than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than Aveanna Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulgent Genetics	$320.35M	1.81	-$60.51M	-$2.39	N/A
Aveanna Healthcare	$2.43B	0.87	$225.03M	$1.18	8.19

Aveanna Healthcare has a net margin of 10.37% compared to Fulgent Genetics' net margin of -23.04%. Aveanna Healthcare's return on equity of 124.68% beat Fulgent Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fulgent Genetics	-23.04%	-3.24%	-2.97%
Aveanna Healthcare	10.37%	124.68%	7.07%

Fulgent Genetics currently has a consensus price target of $27.00, suggesting a potential upside of 32.22%. Aveanna Healthcare has a consensus price target of $10.56, suggesting a potential upside of 9.16%. Given Fulgent Genetics' higher possible upside, equities research analysts plainly believe Fulgent Genetics is more favorable than Aveanna Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Aveanna Healthcare	0 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.67

Fulgent Genetics has a beta of 0.89, suggesting that its stock price is 11% less volatile than the broader market. Comparatively, Aveanna Healthcare has a beta of 1.89, suggesting that its stock price is 89% more volatile than the broader market.

48.1% of Fulgent Genetics shares are held by institutional investors. Comparatively, 88.0% of Aveanna Healthcare shares are held by institutional investors. 36.2% of Fulgent Genetics shares are held by company insiders. Comparatively, 5.3% of Aveanna Healthcare shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Aveanna Healthcare beats Fulgent Genetics on 12 of the 17 factors compared between the two stocks.

How does Fulgent Genetics compare to Addus HomeCare?

Addus HomeCare (NASDAQ:ADUS) and Fulgent Genetics (NASDAQ:FLGT) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

In the previous week, Fulgent Genetics had 4 more articles in the media than Addus HomeCare. MarketBeat recorded 6 mentions for Fulgent Genetics and 2 mentions for Addus HomeCare. Addus HomeCare's average media sentiment score of 1.07 beat Fulgent Genetics' score of 0.90 indicating that Addus HomeCare is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Addus HomeCare	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fulgent Genetics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Addus HomeCare has higher revenue and earnings than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than Addus HomeCare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Addus HomeCare	$1.42B	1.43	$95.91M	$5.41	20.12
Fulgent Genetics	$320.35M	1.81	-$60.51M	-$2.39	N/A

Addus HomeCare currently has a consensus target price of $131.50, suggesting a potential upside of 20.80%. Fulgent Genetics has a consensus target price of $27.00, suggesting a potential upside of 32.22%. Given Fulgent Genetics' higher possible upside, analysts plainly believe Fulgent Genetics is more favorable than Addus HomeCare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Addus HomeCare	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.70
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Addus HomeCare has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market. Comparatively, Fulgent Genetics has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market.

Addus HomeCare has a net margin of 6.89% compared to Fulgent Genetics' net margin of -23.04%. Addus HomeCare's return on equity of 9.80% beat Fulgent Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Addus HomeCare	6.89%	9.80%	7.34%
Fulgent Genetics	-23.04%	-3.24%	-2.97%

95.4% of Addus HomeCare shares are owned by institutional investors. Comparatively, 48.1% of Fulgent Genetics shares are owned by institutional investors. 4.1% of Addus HomeCare shares are owned by company insiders. Comparatively, 36.2% of Fulgent Genetics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Addus HomeCare beats Fulgent Genetics on 12 of the 17 factors compared between the two stocks.

Get Fulgent Genetics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FLGT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FLGT vs. The Competition

Export

Metric	Fulgent Genetics	MEDICAL INFO SYS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$583.64M	$1.81B	$7.05B	$12.61B
Dividend Yield	N/A	N/A	2.68%	8.00%
P/E Ratio	-8.54	77.24	27.11	24.26
Price / Sales	1.81	7.33	589.18	117.88
Price / Cash	N/A	27.39	29.22	49.36
Price / Book	0.57	5.62	10.73	6.29
Net Income	-$60.51M	-$54.76M	$3.58B	$330.66M
7 Day Performance	-2.85%	-2.15%	-2.11%	-1.35%
1 Month Performance	9.31%	5.30%	3.27%	-0.64%
1 Year Performance	6.80%	0.86%	26.32%	19.08%

Fulgent Genetics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FLGT Fulgent Genetics	3.2342 of 5 stars	$20.42 -0.6%	$27.00 +32.2%	+6.0%	$583.64M	$320.35M	N/A	1,315	News Coverage Gap Down
HTFL Heartflow	3.5921 of 5 stars	$27.29 +0.7%	$37.00 +35.6%	N/A	$2.35B	$176.03M	N/A	699	News Coverage Positive News Insider Trade
SGRY Surgery Partners	2.8332 of 5 stars	$17.17 +1.0%	$22.18 +29.2%	-27.5%	$2.25B	$3.31B	N/A	16,000
VRDN Viridian Therapeutics	3.7482 of 5 stars	$20.47 +7.8%	$38.79 +89.5%	+11.4%	$2.11B	$70.85M	N/A	50	Positive News Analyst Downgrade
AVAH Aveanna Healthcare	4.0592 of 5 stars	$9.60 +0.7%	$10.50 +9.4%	+138.2%	$2.09B	$2.43B	8.14	35,500

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FLGT) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Fulgent Genetics (FLGT) Competitors

FLGT vs. HTFL, SGRY, VRDN, AVAH, and ADUS

How does Fulgent Genetics compare to Heartflow?

Summary

How does Fulgent Genetics compare to Surgery Partners?

Summary

How does Fulgent Genetics compare to Viridian Therapeutics?

Summary

How does Fulgent Genetics compare to Aveanna Healthcare?

Summary

How does Fulgent Genetics compare to Addus HomeCare?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLGT vs. The Competition

Fulgent Genetics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Fulgent Genetics (FLGT) Competitors

FLGT vs. HTFL, SGRY, VRDN, AVAH, and ADUS

How does Fulgent Genetics compare to Heartflow?

Do insiders & institutionals hold more shares of HTFL or FLGT?

Which has stronger earnings & valuation, HTFL or FLGT?

Does the media prefer HTFL or FLGT?

Do analysts prefer HTFL or FLGT?

Is HTFL or FLGT more profitable?

Summary

How does Fulgent Genetics compare to Surgery Partners?

Do institutionals & insiders hold more shares of SGRY or FLGT?

Do analysts prefer SGRY or FLGT?

Which has more volatility & risk, SGRY or FLGT?

Does the media favor SGRY or FLGT?

Which has higher valuation and earnings, SGRY or FLGT?

Is SGRY or FLGT more profitable?

Summary

How does Fulgent Genetics compare to Viridian Therapeutics?

Do institutionals & insiders believe in VRDN or FLGT?

Do analysts recommend VRDN or FLGT?

Which has stronger valuation & earnings, VRDN or FLGT?

Is VRDN or FLGT more profitable?

Which has more volatility and risk, VRDN or FLGT?

Does the media favor VRDN or FLGT?

Summary

How does Fulgent Genetics compare to Aveanna Healthcare?

Does the media prefer FLGT or AVAH?

Which has preferable valuation and earnings, FLGT or AVAH?

Is FLGT or AVAH more profitable?

Do analysts recommend FLGT or AVAH?

Which has more risk & volatility, FLGT or AVAH?

Do institutionals and insiders have more ownership in FLGT or AVAH?

Summary

How does Fulgent Genetics compare to Addus HomeCare?

Does the media favor ADUS or FLGT?

Which has preferable valuation & earnings, ADUS or FLGT?

Do analysts rate ADUS or FLGT?

Which has more volatility & risk, ADUS or FLGT?

Is ADUS or FLGT more profitable?

Do institutionals and insiders hold more shares of ADUS or FLGT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLGT vs. The Competition

Fulgent Genetics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools